Cargando…
Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors
Brain GABA(Α) receptors are ionotropic receptors belonging to the class of Cys-loop receptors and are important drug targets for the treatment of anxiety and sleep disorders. By screening a compound library (2,112 compounds) at recombinant human α(4)β(1)δ GABA(Α) receptors heterologously expressed i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308271/ https://www.ncbi.nlm.nih.gov/pubmed/32572053 http://dx.doi.org/10.1038/s41598-020-66821-0 |
_version_ | 1783548954677346304 |
---|---|
author | Falk-Petersen, Christina Birkedahl Tsonkov, Tsonko M. Nielsen, Malene Sofie Harpsøe, Kasper Bundgaard, Christoffer Frølund, Bente Kristiansen, Uffe Gloriam, David E. Wellendorph, Petrine |
author_facet | Falk-Petersen, Christina Birkedahl Tsonkov, Tsonko M. Nielsen, Malene Sofie Harpsøe, Kasper Bundgaard, Christoffer Frølund, Bente Kristiansen, Uffe Gloriam, David E. Wellendorph, Petrine |
author_sort | Falk-Petersen, Christina Birkedahl |
collection | PubMed |
description | Brain GABA(Α) receptors are ionotropic receptors belonging to the class of Cys-loop receptors and are important drug targets for the treatment of anxiety and sleep disorders. By screening a compound library (2,112 compounds) at recombinant human α(4)β(1)δ GABA(Α) receptors heterologously expressed in a HEK cell line, we identified a scaffold of spirocyclic compounds with nanomolar antagonist activity at GABA(Α) receptors. The initial screening hit 2027 (IC(50) of 1.03 μM) was used for analogue search resulting in 018 (IC(50) of 0.088 μM). 018 was most potent at α(3,4,5)-subunit containing receptors, thus showing preference for forebrain-expressed extrasynaptic receptors. Schild analysis of 018 at recombinant human α(4)β(1)δ receptors and displacement of [(3)H]muscimol binding in rat cortical homogenate independently confirmed a competitive profile. The antagonist profile of 018 was further validated by whole-cell patch-clamp electrophysiology, where kinetic studies revealed a slow dissociation rate and a shallow hill slope was observed. Membrane permeability studies showed that 2027 and 018 do not cross membranes, thus making the compounds less attractive for studying central GABA(Α) receptors effects, but conversely more attractive as tool compounds in relation to emerging peripheral GABA(Α) receptor-mediated effects of GABA e.g. in the immune system. |
format | Online Article Text |
id | pubmed-7308271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73082712020-06-23 Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors Falk-Petersen, Christina Birkedahl Tsonkov, Tsonko M. Nielsen, Malene Sofie Harpsøe, Kasper Bundgaard, Christoffer Frølund, Bente Kristiansen, Uffe Gloriam, David E. Wellendorph, Petrine Sci Rep Article Brain GABA(Α) receptors are ionotropic receptors belonging to the class of Cys-loop receptors and are important drug targets for the treatment of anxiety and sleep disorders. By screening a compound library (2,112 compounds) at recombinant human α(4)β(1)δ GABA(Α) receptors heterologously expressed in a HEK cell line, we identified a scaffold of spirocyclic compounds with nanomolar antagonist activity at GABA(Α) receptors. The initial screening hit 2027 (IC(50) of 1.03 μM) was used for analogue search resulting in 018 (IC(50) of 0.088 μM). 018 was most potent at α(3,4,5)-subunit containing receptors, thus showing preference for forebrain-expressed extrasynaptic receptors. Schild analysis of 018 at recombinant human α(4)β(1)δ receptors and displacement of [(3)H]muscimol binding in rat cortical homogenate independently confirmed a competitive profile. The antagonist profile of 018 was further validated by whole-cell patch-clamp electrophysiology, where kinetic studies revealed a slow dissociation rate and a shallow hill slope was observed. Membrane permeability studies showed that 2027 and 018 do not cross membranes, thus making the compounds less attractive for studying central GABA(Α) receptors effects, but conversely more attractive as tool compounds in relation to emerging peripheral GABA(Α) receptor-mediated effects of GABA e.g. in the immune system. Nature Publishing Group UK 2020-06-22 /pmc/articles/PMC7308271/ /pubmed/32572053 http://dx.doi.org/10.1038/s41598-020-66821-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Falk-Petersen, Christina Birkedahl Tsonkov, Tsonko M. Nielsen, Malene Sofie Harpsøe, Kasper Bundgaard, Christoffer Frølund, Bente Kristiansen, Uffe Gloriam, David E. Wellendorph, Petrine Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors |
title | Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors |
title_full | Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors |
title_fullStr | Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors |
title_full_unstemmed | Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors |
title_short | Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors |
title_sort | discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic gaba(a) receptors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308271/ https://www.ncbi.nlm.nih.gov/pubmed/32572053 http://dx.doi.org/10.1038/s41598-020-66821-0 |
work_keys_str_mv | AT falkpetersenchristinabirkedahl discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors AT tsonkovtsonkom discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors AT nielsenmalenesofie discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors AT harpsøekasper discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors AT bundgaardchristoffer discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors AT frølundbente discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors AT kristiansenuffe discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors AT gloriamdavide discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors AT wellendorphpetrine discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors |